Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 594

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 594
---
 mutation, that demonstrate the compounds’ potential to advance the treatment of Parkinson’s Disease (PD). The compounds may be used by NLS pursuant to its license agreement with Aexon Labs, Inc. Using the “Alpha -Synuclein( α -synuclein) A53T Parkinson’s Disease Genetic Cell -BasedAgonist Neurite Outgrowth Assay” by Eurofins, various DOXA compounds demonstrated positive effects on neurite outgrowth, a critical parameter of neuronal health and regeneration. Neurite outgrowth, a critical parameter of neuronal health, was measured using high -contentimaging systems to determine the efficacy of AEX compounds. Reducing α -synucleinaggregation or promoting its clearance can alleviate its toxic effects on neurons. The effects of AEX compounds on neurite outgrowth as well as their impact on Cathepsin D (CTSD) and Orexin 1 Receptor (OX1R) activities provide insights into their potential to modulate the impact of α -synuclein. Key findings • AEX -23: Its pronounced action as an OX1R agonist combined with positive effects on neurite outgrowth at specific concentrations suggests that it may modulate neuronal health through pathways influencing α -synucleindynamics, making it a potential therapeutic candidate to improve neuronal connectivity and resilience in PD. • AEX -19: Its effects at low concentrations on neurite growth coupled with OX1R agonist activity and a moderate increase in CTSD activity suggest potential neuroprotective benefits in PD. • AEX -24: The increase in CTSD activity and agonist activity on OX1R suggests the potential to enhance α -synucleindegradation, highlighting its promising therapeutic impact on PD.

| Moore Financial Consulting |

Annex E-40

AEX -23and AEX -19, which target OX1R, show promise in modulating the effects of α -synucleinon neurons, offering potential benefits in treating synucleinopathies like PD. AEX -19and AEX -24also present intriguing possibilities due to their effects on CTSD activity, suggesting pathways for reducing α -synucleinaggregation. Further in vitroresearch and in vivopreclinical studies are necessary to elucidate the precise mechanisms, optimize dosing, and evaluate the long -termefficacy and safety of these compounds in preclinical and clinical settings. NLS Therapeutics financials: Following are the Company’s Balance sheets as of December 31